CN1075498C - New compound and its derivatives and their use - Google Patents
New compound and its derivatives and their use Download PDFInfo
- Publication number
- CN1075498C CN1075498C CN97111787A CN97111787A CN1075498C CN 1075498 C CN1075498 C CN 1075498C CN 97111787 A CN97111787 A CN 97111787A CN 97111787 A CN97111787 A CN 97111787A CN 1075498 C CN1075498 C CN 1075498C
- Authority
- CN
- China
- Prior art keywords
- formula
- safflower
- present
- compound
- novel compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a novel compound extracted from safflower and a derivant thereof. The novel compound extracted from safflower has a general formula with a chemical structure of a formula [1] and the activity of the antagonistic effect of calcium ions. In addition, the present invention also relates to the applications of the novel compound extracted from safflower and the derivant thereof on an aspect for preparing medicine, particularly to the applications on an aspect for preparing medicine for treating cardiovascular diseases.
Description
A kind of cinnamophenone C glucoside that the present invention relates to extract from safflower the invention still further relates to the purposes of this cinnamophenone C glucoside aspect the preparation medicine, the particularly purposes aspect the medicine of preparation treatment cardiovascular disorder.
Safflower is the dried floral of composite family (Compositae) plant Carthamus tinctorius, has the promoting blood circulation to restore menstrual flow effect, is widely used for gynaecopathia and cardiopathic treatment clinically.According to the record of modern Clinical Application and Chinese medicine book on Chinese herbal medicine usage, we have selected neonatal rat myocardial cell to cultivate is the pharmacologically active index, and the effective constituent of safflower has been carried out detailed tracking separation and successfully obtained its effective constituent.Six kinds of new compounds are arranged in these compositions, 15 kinds of isolated compounds from safflower first, comprising cinnamophenone C glucoside of the present invention, but also found that this cinnamophenone C glucoside has powerful calcium antagonism activity, thereby be accomplished the present invention.
One of purpose of the present invention provides the cinnamophenone C glucoside of a kind of general formula for (1):
Formula (1) wherein R can be H ,-CH
3Or
Preferred R is H, and Glc is a glucosyl group.
Two of purpose of the present invention provides the purposes of cinnamophenone C glucoside aspect the preparation medicine that a kind of general formula is (1).
It is the purposes of the cinnamophenone of (1) at preparation cerebrocrast and treating cardiovascular disease prescription face that three of purpose of the present invention provides a kind of general formula.
According to the present invention, preferred R is the effective constituent of formula (1) compound of H as disease treatment, can become medicine to them and/or excipient combined preparation, and this pharmaceutical composition has the antagonistic action of calcium ion, can be used for the treatment of cardiovascular disorder.
In order to set forth the present invention better, be exemplified below, but this example is not used for scope of the present invention is limited.The extraction of embodiment 1 formula (1) compound with separate
1) extracts flos carthami with 50% ethanolic soln, reclaim the aqueous solution that obtains this extract behind the ethanol.
2) behind the aqueous solution with the ethyl acetate extraction Flos Carthami extract, adopt macroporous resin and sephadex lh-20 chromatography method to make with extra care with the eluent of 50% second alcohol and water respectively its water-soluble portion, obtain the formula that R is H (1) compound, claim safflower alkali A again.The physical and chemical parameter of this compound is: divide in composition: C
27H
29NO
13: molecular weight: 575: high resolution mass spectrometry hrfabms:m/z598.1544[M+Na]
+(calcd598.1537): mass spectrum hrfabms:m/z598[M+Na]
+, 576[M+1]
+, 414; Infrared spectra ir (KBr): υ max3431cm
-1, 1636cm
-1UV spectrum uv: λ max (MeOH) nm (log ε): 250 (3.38), 220 (3.61); [α]
25 D-297 (c=0.1, MeOH); Proton nmr spectra
1H-Rmr (in pyridine-d
5): δ 8.08 (1H, d, 15.7, H-8), 8.21 (1H, d, 15.7, H-9), (6.84 2H, d, 8.6, H-11,15), 7.50 (2H, d, 8.6, H-12,14), 7.05 (1H, d, 2.1, H-17), 5.44 (1H, d, 7.0, H-18), 4.84 (1H, dd, 7.2,7.0, H-19), 4.62 (1H, m, H-20), (4.23 1H, dd, 9.5,3-4, H-21 α), 4.41 (1H, dd, 9.5,9.5, H-21 β), 4.251H, d, 9.5, H-1), 4.64 (1H, m, H-2), 4.08 (1H, dd, 8.9,8.7, H-3 '), 4.00 (1H, dd, 9.3,9.0, H-4 '), 3.58 (1H, m, H-5 '), 4.27 (1H, dd, 11.6,21, H-6 ' a), 3.93 (1H, dd, 11.6,11.6, H-6 ' b), 13.75 (1H, 16-OH), 18.63 (1H, 5-OH); Carbon-13 nmr spectra
13C-nmr (inDMSO-d
6): δ 185.6 (s, C-1), 114.9 (s, C-2), 142.3 (s, C-3), 78.6 (s, C-4), 196.2 (s, C-5), 109.3 (s, C-6), 180.5 (s, C-7), 118.5 (d, C-8), 141.4 (d, C-9), 126.4 (s, C-10), 130.7 (d, C-11,15), 116.1 (d, C-12,14), 160.0 (s, C-13), 135.1 (s, C-16), 103.5 (d, C-17), 76.1 (d, C-18), 76-(d, C-19), 70.6 (d, C-20), 73.0 (t, C-21), 84.2 (d, C-1 '), (69.4 d, C-2 '), 79.6 (d, C-3 '), 69.2 (d, C-4 ') 78.3 (d, C-5 '), 60.8 (t, C-6 ').
Claims (5)
1. the compound of a formula (1), its chemical general formula is:
Formula (1) wherein R can be H ,-CH
3Or
, Glc is a glucosyl group.
2. according to formula (1) compound of claim 1, the R in its formula of is H.
3. claim 1 or 2 formula (1) compound are used for the purposes of pharmaceutical compositions.
4 according to the purposes described in the claim 3, and pharmaceutical composition wherein is a cerebrocrast.
5. according to the purposes described in the claim 3, pharmaceutical composition wherein is the cardiovascular pharmaceutical composition of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97111787A CN1075498C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97111787A CN1075498C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1199048A CN1199048A (en) | 1998-11-18 |
| CN1075498C true CN1075498C (en) | 2001-11-28 |
Family
ID=5171877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97111787A Expired - Fee Related CN1075498C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1075498C (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4333934A (en) * | 1979-02-09 | 1982-06-08 | Roussel Uclaf | Imidazoquinoxalines and pyrroloquinoxalines |
| EP0090516A1 (en) * | 1982-03-16 | 1983-10-05 | Pfizer Inc. | Substituted hexahydropyrrolo(1,2-a)-quinoline, hexahydro-1H-pyrido(1,2-a)-quinoline, hexahydrobenzo(3)indene and octahydrophenanthrene CNS agents |
| US4576964A (en) * | 1982-03-16 | 1986-03-18 | Pfizer Inc. | Substituted hexahydrobenzo[e]indene and octahydrophenanthrene CNS agents and pharmaceutical compositions thereof |
| US4644002A (en) * | 1979-02-09 | 1987-02-17 | Roussel Uclaf | Imidazo[2,1-C]quinolines, useful as antiallergic agents |
-
1997
- 1997-05-08 CN CN97111787A patent/CN1075498C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4333934A (en) * | 1979-02-09 | 1982-06-08 | Roussel Uclaf | Imidazoquinoxalines and pyrroloquinoxalines |
| US4644002A (en) * | 1979-02-09 | 1987-02-17 | Roussel Uclaf | Imidazo[2,1-C]quinolines, useful as antiallergic agents |
| EP0090516A1 (en) * | 1982-03-16 | 1983-10-05 | Pfizer Inc. | Substituted hexahydropyrrolo(1,2-a)-quinoline, hexahydro-1H-pyrido(1,2-a)-quinoline, hexahydrobenzo(3)indene and octahydrophenanthrene CNS agents |
| US4476131A (en) * | 1982-03-16 | 1984-10-09 | Pfizer Inc. | Substituted hexahydropyrrolo[1,2-a]-quinolines, hexahydro-1H-pyrido[1,2-a]-q |
| US4576964A (en) * | 1982-03-16 | 1986-03-18 | Pfizer Inc. | Substituted hexahydrobenzo[e]indene and octahydrophenanthrene CNS agents and pharmaceutical compositions thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1199048A (en) | 1998-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Codington et al. | Pyrimidine Nucleosides. VII. Reactions of 2', 3', 5'-Trimesyloxyuridine1 | |
| US7682638B2 (en) | Use of hederagenin 3-O-α-L-rhamnopyranosyl(1-2)-[β-D-glucopyranosyl(1-4)]-α-L-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors | |
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| US5674900A (en) | Terpenoid-type quinones for treatment of diabetes | |
| CN103665082B (en) | Hemsleya cucurbitane tetracyclic triterpenoid compound, pharmaceutical compositions containing same and application of compound and pharmaceutical composition | |
| WO2003080634A1 (en) | Novel glucopyranoside and a process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof | |
| CN102504006A (en) | Steroid saponin compound in siberian fritillary bulb | |
| Kartal et al. | Two new triterpene saponins from Eryngium campestre | |
| US6777392B2 (en) | 8-(C-β-D-glucopyranosyl)-7, 3', 4'-trihydroxyflavone, process of isolation thereof, pharmaceutical composition and method for the treatment of diabetes | |
| CN101074223B (en) | Versulin derivative and its use in treatment of diabetes and its complication | |
| WO2022215441A1 (en) | Novel polyphenol compound | |
| D'Agostino et al. | Flavonoid glycosides of Alchemilla vulgaris L. | |
| CN103626824B (en) | Hemsleya amabilis cucurbitane tetracyclic triterpene compound, pharmaceutical composition comprising compound and application of pharmaceutical composition and compound | |
| KR101071785B1 (en) | Composition for Treating Atopic Dermatitis Comprising Taxifolin 3-Ｏ-β-D-Glucopyranoside Isolated from the Extract of the Roots of Rhododendron mucronulatum as an Active Ingredient | |
| Aslanipour et al. | Secondary metabolites from Astragalus karjaginii BORISS and the evaluation of their effects on cytokine release and hemolysis | |
| KR100750500B1 (en) | Novel Sargachromanol derivatives, a isolation method thereof, and a composition containing the same showing antioxidant activity | |
| Meyre-Silva et al. | Phytochemical and pharmacological analysis of Bauhinia microstachya (Raddi) Macbr.(Leguminosae) | |
| CN1075498C (en) | New compound and its derivatives and their use | |
| JP2005528398A (en) | Novel glucopyranoside, separation method thereof, drug containing the same and method of use thereof | |
| CN1100039C (en) | New compound and its derivatives and their use | |
| CN111233886B (en) | Dearylated isopentenyl acylated phloroglucinol heteroterpenoid compound and pharmaceutical composition and application thereof | |
| CN100577176C (en) | Extractive of Chinese globeflower in short petal, effective content of anti inflammation and usage | |
| US20090221517A1 (en) | Biologically Active Compounds | |
| US20040044067A1 (en) | Toralactone and its derivation and the use of decreasing blood-fat and losing weight | |
| Shaker et al. | A new triterpenoid saponin from Ononis spinosa and two new flavonoid glycosides from Ononis vaginalis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |